IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation

doi:10.17305/bjbms.2022.7279

	IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
	Xu, Yipeng 8,9,10; Pachnikova, Gabriela 2,3,4,5; Wang, He ; Wu, Yaoyao 7; Przybilla, Dorothea 2,3,4,5; Schaefer, Reinhold 2,3,4,5; Chen, Zihao 1; Zhu, Shaoxing 8,9,10; Keilholz, Ulrich 2,3,4,5,6
刊名	BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
	2022
卷号	22
关键词	IC50 docetaxel spheroids drug testing preclinical models prostate cancer 2D clinical models 3D clinical models cell culture
ISSN号	1512-8601
DOI	10.17305/bjbms.2022.7279
通讯作者	Zhu, Shaoxing(zhusx@zjcc.org.cn) ; Keilholz, Ulrich(ulrich.keilholz@charite.de)
英文摘要	Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2D experiments, suggesting limitations of 3D drug testing. To simulate the natural response of human cells to the drug, we detected the half-maximal inhibitory concentration (IC50) changes of 2D/3D LNCaP cells in the drug docetaxel, as well as the sensitivity of different morphologies of 2D/3D LNCaP to docetaxel treatment. In contrast to 2D LNCaP cells, the evaluation of LNCaP spheroids' susceptibility to treatment was more complicated; the fitness of IC50, curves of 2D and 3D tumor cell preclinical models differs significantly. IC50 curves were unsuitable for large-sized LNCaP spheroids. More evaluation indexes (such as max inhibition) and experiments (such as spheroids formation) should be explored and performed to evaluate the susceptibility systematically.
资助项目	Natural Science Foundation of Zhejiang Province[LQ20H160007] ; ZAST International Medical Cooperation Programme
WOS关键词	PATIENT-DERIVED XENOGRAFTS ; MODELS ; CULTURES ; GROWTH
WOS研究方向	Research & Experimental Medicine
语种	英语
出版者	ASSOC BASIC MEDICAL SCI FEDERATION BOSNIA & HERZEGOVINA SARAJEVO
WOS记录号	WOS:000876747500002
资助机构	Natural Science Foundation of Zhejiang Province ; ZAST International Medical Cooperation Programme
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/130132]
专题	中国科学院合肥物质科学研究院
通讯作者	Zhu, Shaoxing; Keilholz, Ulrich
作者单位	1.Southern Med Univ, Dept Urol, Guangzhou, Peoples R China 2.Berlin Inst Hlth, Berlin, Germany 3.Charite, Ctr Comprehens Canc, Berlin, Germany 4.Free Univ Berlin, Berlin, Germany 5.Humboldt Univ, Berlin, Germany 6.German Canc Consortium DKTK, Heidelberg, Germany 7.Zhejiang Chinese Med Univ, Clin 2, Med Coll, Hangzhou, Zhejiang, Peoples R China 8.Univ Chinese Acad Sci, Canc Hosp, Dept Urol, Zhejiang Canc Hosp, Hangzhou, Peoples R China 9.Key Lab Zhejiang Prov Aptamers & Theranost, Hangzhou, Peoples R China 10.Chinese Acad Sci, Inst Basic Med & Canc, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Xu, Yipeng,Pachnikova, Gabriela,Wang, He,et al. IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation[J]. BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES,2022,22.
APA	Xu, Yipeng.,Pachnikova, Gabriela.,Wang, He.,Wu, Yaoyao.,Przybilla, Dorothea.,...&Keilholz, Ulrich.(2022).IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation.BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES,22.
MLA	Xu, Yipeng,et al."IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation".BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES 22(2022).